Lukas Prchal

Lukas Prchal

Auto-generated profile, based on publicly available information

Lukas Prchal

Biomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, Hradec Kralove 500 05, Czech Republic

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in Ecotoxicology and Environmental Safety
Verified
Journal Article
Closed access
Ivan VokřálIvan Vokřál
Ivan Vokřál
ŠMŠadibolová Michaela
Šadibolová Michaela
PRPodlipná Radka
Podlipná Radka
LJLamka Jiří
Lamka Jiří
PLPrchal Lukáš
Prchal Lukáš
SLSkálová Lenka
Skálová Lenka

1 June 2015 in Molecular and Biochemical Parasitology
Verified
Journal Article
Closed access
LLLenka Lecová
Lenka Lecová
MRMichaela Růžičková
Michaela Růžičková
RLRoz Laing
Roz Laing
HVHeiko Vogel
Heiko Vogel
BSBarbora Szotakova
Barbora Szotakova
PMPetra Matouskova
Petra Matouskova

21 March 2016 in Environmental Science and Pollution Research
Verified
Journal Article
Closed access
PDF file
LPLukáš Prchal
Lukáš Prchal
Radka PodlipnáRadka Podlipná
Radka Podlipná
JLJiří Lamka
Jiří Lamka
TDTereza Dědková
Tereza Dědková
LSLenka Skalova
Lenka Skalova
BSBarbora Szotakova
Barbora Szotakova

9 September 2014 in Parasitology
Verified
Journal Article
Closed access
PDF file
LLLenka Lecová
Lenka Lecová
LSL. Stuchlíková
L. Stuchlíková
LPL. Prchal
L. Prchal
LSLenka Skalova
Lenka Skalova
SUMMARY: Monepantel (MOP), a new anthelmintic drug from a group of amino-acetonitrile derivatives, has been intensively studied during last years. Many authors examined this new drug from different perspectives, e.g. efficacy against different species and stages of parasites, mode of action, metabolism, pharmacokinetics, toxicity, resistance, ecotoxicity, etc. MOP is an anthelmintic for livestock (currently only sheep and goats), with molecular mode of action which is different to all other anthelmintics. MOP has a broad-spectrum of activity against gastrointestinal nematodes of sheep, including adults and L4larvae of the most important species. The key feature of MOP is its full effectiveness against strains of nematodes resistant to benzimidazoles, levamisole, macrocyclic lactones and closantel. After oral administration, MOP is quickly absorbed into the bloodstream and quickly metabolized to MOP sulfone that has a similar efficacy as the parent molecule. Several other MOP metabolites formed in ovine hepatocytes were described. MOP and its metabolites are considered to be non-toxic to environment and its components, such as soil microflora, aquatic organisms, dung organisms, vegetation, etc. The aim of the presented review was not to collect all reported data but to bring an overview of various approaches in the study of MOP and to evaluate their principal results.

1 May 2012 in Parasitology
Verified
Journal Article
Closed access
PDF file
Ivan VokřálIvan Vokřál
Ivan Vokřál
HBHana Bártíková
Hana Bártíková
LPLukáš Prchal
Lukáš Prchal
LSLucie Stuchlíková
Lucie Stuchlíková
LSLenka Skalova
Lenka Skalova
VKVladimír Kubíček
Vladimír Kubíček
SUMMARY: Haemonchus contortus is one of the most pathogenic parasites of small ruminants (e.g. sheep and goat). The treatment of haemonchosis is complicated because of recurrent resistance of H. contortus to common anthelmintics. The aim of this study was to compare the metabolism of the anthelmintic drug flubendazole (FLU) and the activities of selected biotransformation enzymes towards model xenobiotics in 4 different strains of H. contortus: the ISE strain (susceptible to common anthelmintics), ISE-S (resistant to ivermectin), the BR strain (resistant to benzimidazole anthelmintics) and the WR strain (resistant to all common anthelmintics). H. contortus adults were collected from the abomasums from experimentally infected lambs. The in vitro as well as ex vivo experiments were performed and analysed using HPLC with spectrofluorimetric and mass-spectrometric detection. In all H. contortus strains, 4 different FLU metabolites were detected: FLU with a reduced carbonyl group (FLU-R), glucose conjugate of FLU-R and 2 glucose conjugates of FLU. In the resistant strains, the ex vivo formation of all FLU metabolites was significantly higher than in the susceptible ISE strain. The multi-resistant WR strain formed approximately 5 times more conjugates of FLU than the susceptible ISE strain. The in vitro data also showed significant differences in FLU metabolism, in the activities of UDP-glucosyltransferase and several carbonyl-reducing enzymes between the susceptible and resistant H. contortus strains. The altered activities of certain detoxifying enzymes might protect the parasites against the toxic effect of the drugs as well as contribute to drug-resistance in these parasites.

29 October 2019 in Current Alzheimer Research
Verified
Journal Article
Closed access
PDF file
EMEva Mezeiova
Eva Mezeiova
KCKatarina Chalupova
Katarina Chalupova
Eugenie  NepovimovaEugenie Nepovimova
Eugenie Nepovimova
LGLukas Gorecki
Lukas Gorecki
LPLukas Prchal
Lukas Prchal
Jan KorabecnyJan Korabecny
Jan Korabecny
: Alzheimer's Disease (AD) is a neurodegenerative disorder with an increasing impact on society. Because currently available therapy has only a short-term effect, a huge number of novel compounds are developed every year exploiting knowledge of the various aspects of AD pathophysiology. To better address the pathological complexity of AD, one of the most extensively pursued strategies by medicinal chemists is based on Multi-target-directed Ligands (MTDLs). Donepezil is one of the currently approved drugs for AD therapy acting as an acetylcholinesterase inhibitor. In this review, we have made an extensive literature survey focusing on donepezil-derived MTDL hybrids primarily targeting on different levels cholinesterases and amyloid beta (Aβ) peptide. The targeting includes direct interaction of the compounds with Aβ, AChE-induced Aβ aggregation, inhibition of BACE-1 enzyme, and modulation of biometal balance thus impeding Aβ assembly.